Humanigen, Inc.

Passed

Class Action Period:
May 16, 2020 - July 12, 2022

Lead Plaintiff Deadline:
October 25, 2022

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(i) Humanigen's lead product candidate, lenzilumab, posed risks to patients in addition to those disclosed by defendants; (ii) lenzilumab was not the only immunomodulator currently in late-stage clinical trials; (iii) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (v) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until October 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.